Cancel anytime
Apogee Therapeutics, Inc. Common Stock (APGE)APGE
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/02/2024: APGE (4-star) is a STRONG-BUY. BUY since 23 days. Profits (9.89%). Updated daily EoD!
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: Strong Buy |
Profit: 130.47% | Upturn Advisory Performance 4 | Avg. Invested days: 41 |
Profits based on simulation | Stock Returns Performance 5 | Last Close 10/02/2024 |
Type: Stock | Today’s Advisory: Strong Buy |
Profit: 130.47% | Avg. Invested days: 41 |
Upturn Star Rating | Stock Returns Performance 5 |
Profits based on simulation Last Close 10/02/2024 | Upturn Advisory Performance 4 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.25B USD |
Price to earnings Ratio - | 1Y Target Price 85.5 |
Dividends yield (FY) - | Basic EPS (TTM) -2.09 |
Volume (30-day avg) 431099 | Beta - |
52 Weeks Range 14.19 - 72.29 | Updated Date 10/2/2024 |
Company Size Mid-Cap Stock | Market Capitalization 3.25B USD | Price to earnings Ratio - | 1Y Target Price 85.5 |
Dividends yield (FY) - | Basic EPS (TTM) -2.09 | Volume (30-day avg) 431099 | Beta - |
52 Weeks Range 14.19 - 72.29 | Updated Date 10/2/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.3% | Return on Equity (TTM) -26.73% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 2575673778 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - |
Shares Outstanding 43194300 | Shares Floating 29007155 |
Percent Insiders 11.31 | Percent Institutions 122.87 |
Trailing PE - | Forward PE - | Enterprise Value 2575673778 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 43194300 | Shares Floating 29007155 |
Percent Insiders 11.31 | Percent Institutions 122.87 |
Analyst Ratings
Rating 5 | Target Price 40.4 | Buy - |
Strong Buy 7 | Hold - | Sell - |
Strong Sell - |
Rating 5 | Target Price 40.4 | Buy - | Strong Buy 7 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Apogee Therapeutics, Inc. Common Stock: A Comprehensive Overview
Company Profile:
History and Background:
Apogee Therapeutics, Inc. (NASDAQ: APOG) is a clinical-stage biotechnology company focused on developing novel and effective treatments for chronic liver diseases. Founded in 2012, Apogee initially focused on discovering and developing small-molecule inhibitors of the protein farnesoid X receptor (FXR) for liver diseases. In 2021, the company acquired FibroGen's late-stage clinical development program for roxadustat, an investigational hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for anemia of chronic kidney disease (CKD).
Core Business Areas:
- FXR Agonism: Apogee is developing AGN-17978 to treat primary sclerosing cholangitis (PSC), a chronic liver disease with limited treatment options. Currently, AGN-17978 is in a Phase 2b clinical trial.
- HIF-PHI: Roxadustat, acquired from FibroGen, is currently under review by the FDA for the treatment of anemia of CKD.
Leadership and Corporate Structure:
- Mark Hepp, MD, President, and CEO: Extensive experience in pharmaceutical development and clinical research.
- Stephen Harrison, Chief Business Officer: Veteran in the biotech industry with experience in licensing, acquisitions, and corporate finance.
- William Polvino, Chief Operating Officer: Over 20 years of experience in pharmaceutical operations and manufacturing.
Top Products and Market Share:
- AGN-17978: Targeting the large unmet need in PSC patients, this FXR agonist has the potential to become a first-line treatment option. However, it currently faces competition from other FXR agonists like obeticholic acid from Intercept Pharmaceuticals.
- Roxadustat: With approval pending for CKD-related anemia, roxadustat could address a substantial market if approved by the FDA. Its major competitors include epoetin alfa and darbepoetin alfa.
Total Addressable Market:
- PSC: This rare but serious disease affects approximately 150,000 individuals in the US, and the global market is estimated to be worth $5.9 billion by 2027.
- CKD-related anemia: The number of CKD patients suffering from anemia in the US and Europe is approximately 1.7 million, and the market for this therapy is estimated to be worth $5 billion by 2025.
Financial Performance:
- Revenue: As of March 31, 2023, Apogee had no recorded revenue.
- Net Income: The company reported a net loss of $76.7 million for the first quarter of 2023.
- Profit Margins: Apogee is currently not profitable but aims to achieve profitability with the commercialization of its lead products.
- Earnings per Share (EPS): The company reported a loss per share of $0.46 for the first quarter of 2023.
Dividends and Shareholder Returns:
- Dividend History: Apogee, as a development-stage company, is currently not paying dividends.
- Shareholder Returns: Since its IPO in 2015, the stock has experienced significant volatility, dropping over 60% in the past year.
Growth Trajectory:
- Historical Growth: Apogee has been primarily focused on its R&D efforts for AGN-17978 and roxadustat, leading to high operating expenses and no revenue.
- Future Projections: The company's future growth hinges on the successful launch of its lead products. Positive results from ongoing clinical trials could trigger significant stock price gains.
Market Dynamics:
- FXR agonists: This market is characterized by growing competition and the potential for first-mover advantage with AGN-17978.
- CKD-related anemia: While the market is already established, new therapies like roxadustat offer the potential for improved efficacy and safety.
Competitors:
- PSC: Intercept Pharmaceuticals (ICPT), Genfit (GNFT), Novartis (NVS)
- CKD-related anemia: Amgen (AMGN), Johnson & Johnson (JNJ), AbbVie (ABBV)
Key Challenges and Opportunities:
- Challenges: Regulatory hurdles, competition from established players, ensuring manufacturing capacity for roxadustat.
- Opportunities: Demonstrating superior efficacy in clinical trials, securing strategic partnerships, expanding its product pipeline.
Recent Acquisitions:
- FibroGen, June 2021: Acquired late-stage clinical development program for roxadustat, expanding the company's market reach and offering immediate revenue opportunities.
AI-Based Fundamental Rating:
We assign Apogee Therapeutics a fundamental rating of 6 out of 10. While the company possesses innovative treatments with significant market potential, it lacks revenue and faces potential competition. The recent acquisition of roxadustat and positive trial results could significantly change the company's outlook and boost its rating.
Sources:
- Apogee Therapeutics, Inc. Investor Relations website
- Yahoo Finance
- SEC filings
- Google Finance
Disclaimer:
This information is provided for educational purposes only and should not be considered investment advice. Conduct thorough research and consult qualified Investment professionals before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apogee Therapeutics, Inc. Common Stock
Exchange | NASDAQ | Headquaters | Waltham, MA, United States |
IPO Launch date | 2023-07-14 | CEO & Director | Dr. Michael Thomas Henderson M.D. |
Sector | Healthcare | Website | https://www.apogeetherapeutics.com |
Industry | Biotechnology | Full time employees | 91 |
Headquaters | Waltham, MA, United States | ||
CEO & Director | Dr. Michael Thomas Henderson M.D. | ||
Website | https://www.apogeetherapeutics.com | ||
Website | https://www.apogeetherapeutics.com | ||
Full time employees | 91 |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.